Kisunla Side Effects
Generic name: donanemab
Medically reviewed by Drugs.com. Last updated on Sep 10, 2024.
Note: This document provides detailed information about Kisunla Side Effects associated with donanemab. Some dosage forms listed on this page may not apply specifically to the brand name Kisunla.
Applies to donanemab: intravenous solution.
Important warnings
This medicine can cause some serious health issues
Donanemab can cause temporary swelling or bleeding in the brain that usually clears up with time.
This may cause no symptoms but can be serious.
Call your doctor if you have headaches, dizziness, nausea, confusion, trouble walking, seizures, or vision changes.
Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.
Some side effects may occur during the injection. Tell your medical caregiver if you feel dizzy, nauseated, light-headed, itchy, sweaty, or have chills, a headache, chest tightness, back pain, trouble breathing, skin irritation, or swelling in your face.
Donanemab (the active ingredient contained in Kisunla) can cause temporary swelling or bleeding in the brain, especially if you use medication to prevent blood clots.
Call your doctor if you have:
-
dizziness, confusion, headache;
-
vision changes;
-
seizures;
-
vomiting, nausea; or
-
trouble walking.
Common side effects may include:
-
ARIA with symptoms, or with signs that appear on an MRI; or
-
headache.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For healthcare professionals
Applies to donanemab: intravenous solution.
General adverse events
The most frequently reported side effects included amyloid related imaging abnormalities-hemosiderin deposition (ARIA-H) microhemorrhage, ARIA-H superficial siderosis, ARIA-edema (ARIA-E), and headache. The most common side effect resulting in discontinuation was infusion-related reaction.[Ref]
Gastrointestinal
- Uncommon (0.1% to 1%): Intestinal obstruction, intestinal perforation[Ref]
Hypersensitivity
- Common (1% to 10%): Hypersensitivity reactions (including anaphylaxis)[Ref]
Immunologic
- Very common (10% or more): Developed antidrug antibodies (87%), developed neutralizing antibodies (87%)[Ref]
About 10% of patients who developed antidrug antibodies while taking this drug reported infusion-related reactions.[Ref]
Nervous system
- Very common (10% or more): ARIA-H microhemorrhage (25%), ARIA-E (24%), ARIA-H superficial siderosis (15%), headache (13%)[Ref]
Patients have had both microhemorrhage and superficial siderosis.[Ref]
Other
- Common (1% to 10%): Infusion-related reactions[Ref]
References
1. (2024) "Product Information. Kisunla (donanemab)." Lilly, Eli and Company
Frequently asked questions
- How do I decide between Leqembi and Kisunla?
- Will insurance cover Kisunla treatment?
- How well does Kisunla work?
- How long will I need to take Kisunla?
- How quickly does Kisunla start working?
- Can Kisunla be used with other Alzheimer's drugs?
More about Kisunla (donanemab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous central nervous system agents
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Kisunla side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.
